BRPI0208124B8 - uso de um anticorpo igy imunologicamente específico para a proteína paa associada à virulência de escherichia coli de ligação e eliminação (aeec) - Google Patents

uso de um anticorpo igy imunologicamente específico para a proteína paa associada à virulência de escherichia coli de ligação e eliminação (aeec)

Info

Publication number
BRPI0208124B8
BRPI0208124B8 BRPI0208124A BRPI0208124A BRPI0208124B8 BR PI0208124 B8 BRPI0208124 B8 BR PI0208124B8 BR PI0208124 A BRPI0208124 A BR PI0208124A BR PI0208124 A BRPI0208124 A BR PI0208124A BR PI0208124 B8 BRPI0208124 B8 BR PI0208124B8
Authority
BR
Brazil
Prior art keywords
aeec
virulence
immunologically specific
escherichia coli
deleting
Prior art date
Application number
BRPI0208124A
Other languages
English (en)
Inventor
Francis Girard
Isabelle Batisson
M Fairbrother John
Josee Harel
Marie-Pierre Guimond
Original Assignee
Elanco Canada Ltd
Prevtec Microbia Inc
Prevtec Microbia Int Inc
Valorisation Recherche Soc En Comandite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco Canada Ltd, Prevtec Microbia Inc, Prevtec Microbia Int Inc, Valorisation Recherche Soc En Comandite filed Critical Elanco Canada Ltd
Publication of BR0208124A publication Critical patent/BR0208124A/pt
Publication of BRPI0208124B1 publication Critical patent/BRPI0208124B1/pt
Publication of BRPI0208124B8 publication Critical patent/BRPI0208124B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"anticorpos para a prevenção e tratamento de doenças associadas à escherichia coli em ligação e eliminação (aeec)". a presente invenção refere-se a anticorpos imunologicamente específicos para uma proteína associada à virulência de escherichia coli em ligação e eliminação (aeec), produtos, composições e métodos e ao seu. uso na prevenção de uma infecção por aeec em um mamífero. o anticorpo da invenção é imunologicamente específico para uma proteína associada à virulência de aeec e é capaz de prevenir uma infecção intestinal por aeec in vivo quando administrado a um mamífero. o anticorpo da invenção é de preferência útil para prevenção do desenvolvimento de lesões intestinais de a/e associadas à aeec. isso é conseguido de preferência através do uso de anticorpos igy imunologicamente específicos para uma ou mais proteínas associadas à virulência de aeec, tal como eae, tir, espa e paa.
BRPI0208124A 2001-03-15 2002-03-14 uso de um anticorpo igy imunologicamente específico para a proteína paa associada à virulência de escherichia coli de ligação e eliminação (aeec) BRPI0208124B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002339436A CA2339436A1 (fr) 2001-03-15 2001-03-15 Production d'anticorps contre les facteurs de virulence associes aux souches d'escherichia coli aeec, et leur utilisation
CA2,339,436 2001-03-15
PCT/CA2002/000353 WO2002074812A2 (en) 2001-03-15 2002-03-14 Antibodies for preventing and treating attaching and effacing escherichia coli (aeec) associated diseases

Publications (3)

Publication Number Publication Date
BR0208124A BR0208124A (pt) 2004-03-09
BRPI0208124B1 BRPI0208124B1 (pt) 2018-02-06
BRPI0208124B8 true BRPI0208124B8 (pt) 2022-05-10

Family

ID=4168495

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0208124A BRPI0208124B8 (pt) 2001-03-15 2002-03-14 uso de um anticorpo igy imunologicamente específico para a proteína paa associada à virulência de escherichia coli de ligação e eliminação (aeec)

Country Status (9)

Country Link
US (3) US7445782B2 (pt)
EP (1) EP1368379B1 (pt)
AT (1) ATE356147T1 (pt)
AU (1) AU2002242531B8 (pt)
BR (1) BRPI0208124B8 (pt)
CA (1) CA2339436A1 (pt)
DE (1) DE60218636T2 (pt)
ES (1) ES2283531T3 (pt)
WO (1) WO2002074812A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0937148A1 (en) * 1996-04-19 1999-08-25 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
CA2339436A1 (fr) * 2001-03-15 2002-09-15 Josee Harel Production d'anticorps contre les facteurs de virulence associes aux souches d'escherichia coli aeec, et leur utilisation
US7750063B2 (en) 2001-10-24 2010-07-06 Pentron Clinical Technologies, Llc Dental filling material
US7204874B2 (en) 2001-10-24 2007-04-17 Pentron Clinical Technologies, Llc Root canal filling material
US7303817B2 (en) 2001-10-24 2007-12-04 Weitao Jia Dental filling material
EP1563062A1 (en) * 2002-11-14 2005-08-17 Novartis AG Antimicrobial activity of antibodies producing reactive oxygen species
UA115524C2 (uk) 2010-11-23 2017-11-27 Пантерикс, Інк. Композиції та способи лікування у клінічних застосуваннях широкого спектра дії, недиференційованих або змішаних
US8926980B2 (en) * 2011-07-11 2015-01-06 Camas Incorporated Compositions against bacterial toxins
CN102940875B (zh) * 2012-10-31 2015-09-30 中国人民解放军军事医学科学院微生物流行病研究所 Paa蛋白及由其制备的抗体与应用
EP2943211A4 (en) * 2012-12-19 2017-01-25 David Boone Uses of a gastrokine protein
CN105754919B (zh) * 2016-03-22 2019-08-30 南方医科大学 一种ehec o157：h7重组嗜酸乳杆菌载体疫苗及其制备方法和应用
US10772141B2 (en) 2018-06-28 2020-09-08 The Chinese University Of Hong Kong System and method for peer-to-peer wireless communication

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550019A (en) * 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
US4748018A (en) * 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
US5932250A (en) 1982-06-03 1999-08-03 Dcv, Inc. Anti-cholesterolemic egg, vaccine and method for production, and use
JPH0832868B2 (ja) * 1990-01-16 1996-03-29 豊田合成株式会社 液圧シリンダ用シール部品
CA2078716A1 (en) * 1992-09-21 1994-03-22 Joyce De Azavedo Attaching and effacing protein of enterohemorrhagic e. coli
US5367054A (en) * 1993-04-12 1994-11-22 Stolle Research & Development Corp. Large-scale purification of egg immunoglobulin
US5585098A (en) 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
DE9404859U1 (de) 1994-03-22 1995-07-20 Diehl Remscheid Gmbh & Co Verbindung zwischen einem elastischen Gummiteil mit einem harten Kunststoffteil
WO1996000233A1 (en) * 1994-06-24 1996-01-04 Children's Hospital And Medical Center Escherichia coli o157:h7 epithelial adhesin
WO1996030043A1 (en) * 1995-03-24 1996-10-03 Ophidian Pharmaceuticals Treatment for verotoxin-producing escherichia coli
US5972721A (en) * 1996-03-14 1999-10-26 The United States Of America As Represented By The Secretary Of The Air Force Immunomagnetic assay system for clinical diagnosis and other purposes
EP0937148A1 (en) * 1996-04-19 1999-08-25 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
DK0904288T3 (da) 1996-04-23 2012-09-24 Univ British Columbia Patogent Escherichia coli-associeret protein
US5741489A (en) * 1996-05-24 1998-04-21 Anitox Corporation Passively administered antibody that enhances feed conversion efficiency
AU729502B2 (en) * 1996-10-02 2001-02-01 Ovimmune, Inc. Oral administration of chicken yolk antibodies to treat disease
US6204004B1 (en) * 1997-03-21 2001-03-20 University Of Maryland, Baltimore Immunodiagnostic test for enterohemorrhagic Escherichia coli infection
JPH10298105A (ja) * 1997-04-23 1998-11-10 Gen Corp:Kk 腸管出血性大腸菌による感染症の予防剤および治療剤
US7208574B1 (en) * 1997-11-12 2007-04-24 The University Of British Columbia Host receptor for pathogenic bacteria
ES2333630T3 (es) 1997-11-12 2010-02-24 The University Of British Columbia Hp90: receptor de membrana anfitriona para bacterias patogenicas, codificadas por el gen tir bacteriano.
GB9803322D0 (en) 1998-02-16 1998-04-15 Imperial College Methods
DE19910159A1 (de) 1999-02-26 2000-09-14 Rosemarie Heis Spezifische lgY-Eidotterantikörper, ihre Gewinnung und ihre Verwendung
US6291435B1 (en) * 1999-03-04 2001-09-18 The Governs Of The University Of Alberta Treatment of diarrhea caused by enteropathogenic Escherichia coli
US7241443B1 (en) * 1999-07-15 2007-07-10 Camas Incorporated Immunogen adherence inhibitor and method of making and using same
US6162441A (en) * 1999-12-15 2000-12-19 Republic Of Korea (Management: Rural Development Administration) Method for the production of anti-escherichia. coli O157 : H7 antibody
WO2001048018A1 (en) * 1999-12-27 2001-07-05 University Of Manitoba Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic escherichia coli and other pathogens
AU2001249388A1 (en) * 2000-03-24 2001-10-08 Trouw Nutrition Usa Combination of plasma and hyperimmunized products for increased performance
US8173783B2 (en) * 2000-12-08 2012-05-08 Good Biotech Corporation Process for selectively isolating IgY antibodies from egg yolk of an anseriform bird and IgY antibodies obtained thereby
JP2004516333A (ja) * 2001-01-04 2004-06-03 ユニバーシティー オブ サスカチェワン 腸管出血性大腸菌ワクチン
CN1411378A (zh) * 2001-01-05 2003-04-16 鸡蛋高新技术有限公司 含有抗病原菌特异抗体(IgY)的鸡蛋及含有该IgY的酸乳和冰淇淋的生产方法
US6939954B2 (en) * 2001-01-30 2005-09-06 The Lauridsen Group Incorporated Isolated bovine lgG heavy chain protein and its use as an antimicrobial
CA2339436A1 (fr) * 2001-03-15 2002-09-15 Josee Harel Production d'anticorps contre les facteurs de virulence associes aux souches d'escherichia coli aeec, et leur utilisation
IL148598A (en) * 2002-03-10 2008-04-13 Ely Morag Multifunctional complex for targeting specific phagocytosis of a target agent and a composition comprising it
US8329192B2 (en) * 2003-09-19 2012-12-11 Epitopix Llc Campylobacter polypeptides and methods of use
MXPA06013253A (es) * 2004-05-14 2007-02-28 Agtech Products Inc Metodo y composicion para reducir la enfermedad de e. coli disease y mejorar el rendimiento utilizando bacilos.
US7250261B2 (en) * 2004-05-20 2007-07-31 University Of Massachusetts EspFu nucleic acids and proteins and uses thereof

Also Published As

Publication number Publication date
DE60218636T2 (de) 2007-11-15
DE60218636D1 (de) 2007-04-19
EP1368379A2 (en) 2003-12-10
US7445782B2 (en) 2008-11-04
US7727531B2 (en) 2010-06-01
US20090092621A1 (en) 2009-04-09
US20100183627A1 (en) 2010-07-22
AU2002242531B8 (en) 2008-04-03
WO2002074812A2 (en) 2002-09-26
BR0208124A (pt) 2004-03-09
AU2002242531B2 (en) 2007-09-20
ATE356147T1 (de) 2007-03-15
WO2002074812A3 (en) 2003-08-21
ES2283531T3 (es) 2007-11-01
CA2339436A1 (fr) 2002-09-15
BRPI0208124B1 (pt) 2018-02-06
US8623372B2 (en) 2014-01-07
US20040086513A1 (en) 2004-05-06
EP1368379B1 (en) 2007-03-07

Similar Documents

Publication Publication Date Title
BRPI0208124B8 (pt) uso de um anticorpo igy imunologicamente específico para a proteína paa associada à virulência de escherichia coli de ligação e eliminação (aeec)
PT1053325E (pt) Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao.
DK0587780T4 (da) Smitstof, som forårsager Mystery Swine Disease,vaccinepræparater og diagnostiske sæt
BR0207283A (pt) Anticorpos anti-egfr modificados com imunogenicidade reduzida
CY1114179T1 (el) Ανοσοποιηση εναντι μηνιγγιτιδοκοκκου οροομαδας υ με χρηση πρωτεϊνων
BR0112602A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
DE69939747D1 (de) Verfahren von dna-impfung
GB0315450D0 (en) Biological products
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
EA200301250A1 (ru) Фармацевтические композиции, содержащие слаборастворимые и/или чувствительные к кислотам лекарственные средства и нейтрализованные кислотные полимеры
ATE556717T1 (de) Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
ATE460430T1 (de) Kit zur untersuchung von menschlichem niedermolekulargewicht cd14 und antikörper
BR9709958A (pt) Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
DE68925275T2 (de) Endotoxin-bindeprotein und dessen verwendung
DE60125537D1 (de) Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen
WO2006113907A3 (en) Escherichia coli o157:h7 proteins and uses thereof
HUP9901464A2 (hu) Eljárás baktériumtörzsek kiválasztására
DE69530380D1 (de) Retropeptide, antikörper dagegen und deren verwendungen in der impfung und in vitro diagnostik
DK1406927T3 (da) Glycopeptider, fremstilling og anvendelse deraf til diagnosticering eller terapeutisk behandling af dissemineret sklerose
AU666482B2 (en) Human herpesvirus type 6 protein p100, the corresponding DNA sequences, their preparation and use
WO2004065936A3 (en) Immunoglobulin e detection in mammalian species
WO2002036149A3 (en) Methods for obtaining inhibitors of t-cell membrane protein (tirc7) ligand binding and uses thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: PREVTEC MICROBIA INC. (CA)

B25A Requested transfer of rights approved

Owner name: PREVTEC MICROBIA INTERNATIONAL INC. (BB)

B25A Requested transfer of rights approved

Owner name: PREVTEC MICROBIA INC (CA)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22E Other requirements [chapter 22.5 patent gazette]

Free format text: FORMULADA EXIGENCIA PARA ADEQUACAO OU CUMPRIMENTO DE DISPOSICOES LEGAIS NO PRAZO DE 60 (SESSENTA) DIAS DESTA DATA.

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2639 DE 03/08/2021 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved
B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2629 DE 25/05/2021 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO REF. RPI 2457, DE 06/02/2018. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 06/02/2018, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS.